Covance is one of the world’s largest and most comprehensive drug development services companies with more than 10,000 employees in 60 countries. Through its comprehensive portfolio of services, Covance has helped pharmaceutical and biotech companies develop one-third of all prescription medicines in the market today.
Working with clients of all sizes, Covance recognizes that your development program is as unique as the product you bring to our facilities. With >250 different biomolecules successfully supported annually, Covance Biotechnology Services provide you with a global, multidisciplinary team of experts and specialized state-of-the-art infrastructure to help achieve your development and commercialization goals.
The comprehensive Covance biotechnology service capabilities include extensive expertise and experience in:
- cGMP batch release
- Protein chemistry
- Biological assays
- Adventitious agent testing
- cGMP cell bank production and storage
- Biomanufacturing support
- cGMP stability studies
- Immunocharacterization
- Molecular biology
- Viral clearance studies
Covance has a complementary portfolio of discovery, nonclinical safety assessment, clinical development, and market access capabilities for full development of biopharmaceutical products.
We invite you to visit our facilities in North America and in Europe, meet our scientists, and see for yourself how the scientific and regulatory expertise and experience, accumulated and proven through decades of hands-on development of a wide variety of molecules and numerous submissions, make Covance your partner of choice for biopharmaceutical development.
Author Details
Ji Wu, PhD, is marketing manager at Covance, 3301 Kinsman Blvd, Madison, WI 53704, USA; 1-888-268-2623; ji.wu@covance.com.